文献速递炎症性肠病

肺炎球菌结合疫苗在炎症性肠病免疫抑制成人中高免疫原性

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

该开放标签、IV期、多中心研究纳入306例 IBD 成人,评估 PCV13 安全性和免疫原性。接种后中位血清保护率从43.9%升至90.4%(P<0.001),抗TNF组略低于其他免疫抑制方案或非免疫抑制治疗,无安全问题。

要点

  • PCV13接种后中位血清保护率从43.9%升至90.4%(P<0.001)。
  • 抗TNF组血清保护率从44.5%升至86.6%,略低于其他方案。
  • PCV13在IBD成人中高免疫原性且耐受良好,无安全问题。

核心结论

  • PCV13在IBD成人中高免疫原性且耐受良好,无论基线治疗如何,应鼓励所有IBD成人接种。

研究设计与样本

  • 开放标签、IV期、多中心研究,纳入306例IBD成人,2014年3月至2016年2月入组。

主要发现

  • 中位血清保护率从纳入时43.9%(95%CI 42.3-45.5)显著升至接种后90.4%(95%CI 89.5-91.3;P<0.001)。
  • 抗TNF组血清保护率从44.5%(95%CI 42.3%-46.8%)升至86.6%(95%CI 84.9%-88.1%)。
  • 其他免疫抑制方案组(硫嘌呤、甲氨蝶呤、口服糖皮质激素)从44.7%(95%CI 41.7%-47.7%)升至93.8%(95%CI 92.1%-95.2%)。
  • 非免疫抑制治疗组(5-氨基水杨酸、局部糖皮质激素、维得利珠单抗)从41.3%(95%CI 37.9%-44.8%)升至95.2%(95%CI 93.4%-96.6%)。
  • 无安全问题。

关键数值与推荐

  • 排除标准:当前IBD flare、妊娠、过去5年内肺炎球菌免疫、过去4周内流感免疫。
  • PCV13肌内注射,血清型特异性疫苗反应采用调理吞噬试验评估。

临床怎么用

  • PCV13应鼓励用于所有IBD成人,无论基线治疗类型。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with inflammatory bowel disease (IBD) are predisposed to pneumococcal infections due to their underlying disease and iatrogenic immunosuppression. Vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) is recommended, but with poor take-up and few data available. We performed an open-label, phase IV, multicenter study to evaluate the safety and immunogenicity of PCV13 in adults with IBD and to analyze the influence of immunomodulating treatments on anti-pneumococcal seroresponses. METHODS: We enrolled 306 patients with IBD from March 2014 through February 2016, with the following exclusion criteria: current IBD flare, pregnancy, pneumococcal immunization in the previous 5 years, and influenza immunization in the previous 4 weeks. PCV13 was administered intramuscularly. Serotype-specific vaccine responses were evaluated using an opsonophagocytic assay. Adverse events were monitored by diary cards and standardized phone interviews. RESULTS: The median seroprotection rate increased significantly from 43.9% (95% confidence interval [CI], 42.3-45.5) at inclusion to 90.4% (95% CI, 89.5-91.3%; P < 0.001) after vaccination. Patients receiving anti-tumor necrosis factor agents achieved a slightly lower seroprotection rate (from 44.5% [95% CI, 42.3%-46.8%] to 86.6% [95% CI, 84.9%-88.1%]) than patients treated with other types of immunosuppressive regimens (thiopurine, methotrexate, oral corticosteroids; from 44.7% [95% CI, 41.7%-47.7%] to 93.8% [95% CI, 92.1%-95.2%]) or nonimmunosuppressive treatment (5-aminosalicylate, topical corticosteroids, vedolizumab; from 41.3% [95% CI, 37.9%-44.8%] to 95.2% [95% CI, 93.4%-96.6%]). There were no safety issues. DISCUSSION: Overall, the administration of PCV13 was highly immunogenic and well tolerated, irrespective of the baseline treatment, and should be encouraged in all adults with IBD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Pittet LF, Verolet CM, Michetti P, et al. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol. 2019. PMID: 31205131. doi:10.14309/ajg.0000000000000289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。